Lazard Asset Management’s China Biologic Products Holdings, Inc. CBPO Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2021
Q2 | – | Sell |
-1,809
| Closed | -$214K | – | 2154 |
|
|
2021
Q1 | $214K | Buy |
+1,809
| New | +$214K | ﹤0.01% | 1088 |
|
|
2018
Q3 | – | Sell |
-1,570
| Closed | -$155K | – | 1143 |
|
|
2018
Q2 | $155K | Buy |
+1,570
| New | +$136K | ﹤0.01% | 866 |
|
|
2018
Q1 | – | Sell |
-1,600
| Closed | -$126K | – | 1179 |
|
|
2017
Q4 | $126K | Buy |
+1,600
| New | +$133K | ﹤0.01% | 912 |
|
|
2017
Q3 | – | Sell |
-100
| Closed | -$11K | – | 1085 |
|
|
2017
Q2 | $11K | Hold |
100
| – | – | ﹤0.01% | 920 |
|
|
2017
Q1 | $10K | Sell |
100
-6,977
| -99% | -$746K | ﹤0.01% | 948 |
|
|
2016
Q4 | $760K | Sell |
7,077
-1,623
| -19% | -$190K | ﹤0.01% | 707 |
|
|
2016
Q3 | $1.08M | Buy |
8,700
+900
| +12% | +$106K | ﹤0.01% | 670 |
|
|
2016
Q2 | $829K | Buy |
7,800
+600
| +8% | +$69.7K | ﹤0.01% | 702 |
|
|
2016
Q1 | $824K | Buy |
+7,200
| New | +$845K | ﹤0.01% | 685 |
|
|
2015
Q4 | – | Sell |
-53,800
| Closed | -$4.83M | – | 1178 |
|
|
2015
Q3 | $4.83M | Buy |
+53,800
| New | +$5.68M | 0.01% | 490 |
|
Lazard Asset Management's CBPO Position: Q2 2021 in Review
Lazard Asset Management sold out of China Biologic Products Holdings, Inc. (CBPO) in Q2 2021, closing a stake of 1,809 shares — an estimated $214K sold.
Lazard Asset Management first reported a position in CBPO in Q3 2015 and held it in 10 quarters. The position peaked at $4.83M in Q3 2015. 0 funds tracked by Wall St. Rank hold CBPO as of Q2 2021.
- Lazard Asset Management reported no remaining China Biologic Products Holdings, Inc. position as of Q2 2021 after selling out during the quarter.
- Lazard Asset Management sold 1,809 China Biologic Products Holdings, Inc. shares in Q2 2021, an estimated $214K.
- Lazard Asset Management first reported a position in China Biologic Products Holdings, Inc. in Q3 2015 and held it in 10 quarters.
- Lazard Asset Management's China Biologic Products Holdings, Inc. position peaked at $4.83M in Q3 2015.
- 0 funds tracked by Wall St. Rank held China Biologic Products Holdings, Inc. as of Q2 2021.
Based on Lazard Asset Management's 13F filing for Q2 2021, filed 12 Aug 2021.